Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin.

MLA

Shin, HoJin, et al. “Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin.” Annals of Internal Medicine, vol. 175, no. 12, Dec. 2022, p. W155. EBSCOhost, https://doi.org/10.7326/L22-0333.

APA

Shin, H., Schneeweiss, S., Glynn, R. J., & Patorno, E. (2022). Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin. Annals of Internal Medicine, 175(12), W155. https://doi.org/10.7326/L22-0333

Chicago

Shin, HoJin, Sebastian Schneeweiss, Robert J Glynn, and Elisabetta Patorno. 2022. “Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin.” Annals of Internal Medicine 175 (12): W155. doi:10.7326/L22-0333.